Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of modified process hepatitis B vaccine in predialysis and dialysis patients
2006-003650-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Merck & Co. Primary endpoints: Seroprotection rate after 3rd dose and Seroprotection rate after 4th dose. Started Dec 2006; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2006-003650-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003650-20.